文献速递妇科

针对上皮性卵巢癌的靶向手术预防在携带BRCA突变的上皮性卵巢癌女性家庭成员中具有成本效益并节省费用:一项加拿大模型

Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
PubMed 文献 · Gynecol Oncol · 2019-01-28

该加拿大模型模拟比较两组:组1不做突变检测、发生上皮性卵巢癌后治疗;组2对索引患者及其一、二级亲属行级联检测,携带者行降低风险手术。100%手术接受率下预防59例上皮性卵巢癌,检测策略更具成本效益且节省费用。

要点

  • 在100%降低风险手术接受率下,级联检测联合手术预防可预防59例上皮性卵巢癌。
  • 检测策略较不检测策略更具成本效益且费用更低,ICER为-$8919。
  • 50年总费用节省为$2,904,486,其中治疗费用节省$9,660,381,级联检测与降低风险手术增加费用$6,755,895。

核心结论

  • 针对BRCA突变携带者的靶向预防不仅能预防上皮性卵巢癌,而且与发生上皮性卵巢癌后再治疗相比具有成本效益。

研究设计与样本

  • 采用加拿大数据建立患者水平模拟模型,比较两组结局。
  • 组1不做突变检测,发生上皮性卵巢癌后治疗。
  • 组2行级联检测(索引患者BRCA检测,若索引患者或一级亲属阳性则分别检测一级和二级亲属),携带者行降低风险手术。
  • 终点为增量成本效果比(ICER)和预算影响。
  • 模型纳入2786例上皮性卵巢癌女性(1年发病率),其有766名一级和207名二级女性亲属。

主要发现

  • 390例索引病例、366名一级亲属和49名二级亲属存在BRCA突变。
  • 在100%降低风险手术接受率下,预防了59例上皮性卵巢癌。
  • 检测策略优于不检测策略(更有效且费用更低;ICER -$8919)。
  • 50年总费用节省为$2,904,486,系治疗费用节省$9,660,381与级联检测及降低风险手术增加费用$6,755,895相抵。
  • 以每质量调整生命年$100,000为阈值,预防在所有模拟情景中均具成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Survival but not cure rates have improved for epithelial ovarian cancer (EOC), demonstrating the need for effective prevention. Targeted prevention in BRCA carriers by risk reducing surgery (RRS) prevents 80% of cases but incurs additional up-front costs, compensated for by the potential for long term savings from treatment avoidance. Does prevention represent value for money? In the absence of long-term data from prospective trials, determining the cost effectiveness of a prevention strategy requires economic modelling. METHODS: A patient level simulation was developed comparing outcomes between two groups, using Canadian data. Group 1: no mutation testing with treatment if EOC developed. Group 2: cascade testing (index patient BRCA tested and the first and second-degree relatives tested if index patient or first-degree relative respectively were positive) with RRS in carriers. End points were Incremental Cost-Effectiveness Ratio (ICER) and budget impact. RESULTS: 2786 women with EOC (1 year incidence) had 766 first and 207 second-degree female relatives. BRCA mutations were present in 390 index cases, 366 first and 49 second-degree relatives. With 100% RRS uptake, 59 EOC were prevented and testing dominated no testing (more effective and less costly; ICER -$8919). The total cost saving over 50 years was $2,904,486 (cost saving of $9,660,381 in treatment costs versus increased cost from cascade testing/RRS of $6,755,895). At a threshold of $100,000 per QALY, prevention was cost effective in all modelled scenarios. CONCLUSIONS: Targeted prevention in BRCA mutation carriers not only prevents EOC but is cost-effective compared to treating EOC if it develops.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hoskins P, Eccleston A, Hurry M, et al. Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model. Gynecol Oncol. 2019. PMID: 30704745. doi:10.1016/j.ygyno.2019.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。